Vanguard Capital Management
PRLD icon

Vanguard Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Vanguard Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.42M Sell
1,897,370
-112,075
-6% -$550K ﹤0.01% 2937
2026
Q2 		$10.7M Buy
2,009,445
+779,039
+63% +$3.39M ﹤0.01% 2773
2026
Q1 		$4.21M Buy
+1,230,406
New +$3.23M ﹤0.01% 3127

Other funds holding PRLD

Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Vanguard Capital Management's PRLD Position: Q3 2026 in Review

Vanguard Capital Management reduced its Prelude Therapeutics (PRLD) stake by 5.6% in Q3 2026, selling an estimated $550K and leaving 1,897,370 shares worth $7.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2937.

Vanguard Capital Management first reported a position in PRLD in Q1 2026 and has held it in 3 quarters since. The position peaked at $10.7M in Q2 2026. 59 funds tracked by Wall St. Rank hold PRLD as of Q3 2026.

  • Vanguard Capital Management held 1,897,370 shares of Prelude Therapeutics worth $7.42M as of Q3 2026.
  • Vanguard Capital Management sold 112,075 Prelude Therapeutics shares in Q3 2026, an estimated $550K.
  • Prelude Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2937 holding.
  • Vanguard Capital Management first reported a position in Prelude Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Prelude Therapeutics position peaked at $10.7M in Q2 2026.
  • 59 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.